Riboflavin as migraine prophylaxis in adolescents

Athaillah, Athaillah; Dimyati, Yazid; Saing, Johannes H.; Saing, Bistok; Hakimi, Hakimi; Lelo, Aznan

doi:10.14238/pi52.3.2012.132-7

Cited by 13 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a randomized control trial on 48 children with episodic migraine failed to show any difference between a 50% lower dose of 200 mg riboflavin and placebo in reducing the number of headache days, their duration, or the severity of migraine attacks and associated symptoms [ 10 ]. These results are in contrast with the study by Athaillah et al [ 11 ] who performed a randomized controlled trial on 98 adolescents between the ages of 12 and 19. In this study, episodic migraineurs both with and without aura were randomly assigned to receive either placebo or riboflavin 400 mg.…”

Section: Nutraceuticalscontrasting

confidence: 98%

Non-Pharmacological Approaches for Migraine

Puledda

Shields

2018

Neurotherapeutics

View full text Add to dashboard Cite

Migraine is one of the most common and debilitating neurological disorders. However, the efficacy of pharmacological therapies may have unsatisfactory efficacy and can be poorly tolerated. There is a strong need in clinical practice for alternative approaches for both acute and preventive treatment. Occasionally, this need might arise in the context of low-frequency migraneurs who are not keen to use medication or fear the potential side effects. At the opposite end of the spectrum, clinicians might be faced with patients who have proven refractory to numerous medications. These patients may benefit from invasive treatment strategies. In recent years, promising strategies for migraine therapy have emerged alongside a progressively better understanding of the complex pathophysiology underlying this disease. This review discusses the most recent and evidence-based advances in non-pharmacological therapeutic approaches for migraine, offering alternatives to drug treatment for both the commonly encountered episodic cases as well as the more complex migraine phenotypes, which are capable of challenging even the headache specialist.Electronic supplementary materialThe online version of this article (10.1007/s13311-018-0623-6) contains supplementary material, which is available to authorized users.

show abstract

Section: Nutraceuticalscontrasting

confidence: 98%

Non-Pharmacological Approaches for Migraine

Puledda

Shields

2018

Neurotherapeutics

View full text Add to dashboard Cite

show abstract

“…The first positive report of riboflavin benefit in paediatric or adolescent patients was a Class I AHA/ANN study of 98 adolescent patients (aged 12‐19 years old) with IHS criteria headache. Patients were randomized in a double‐blind controlled format to receive either 400 mg/d of riboflavin or placebo for 3 months.…”

Section: Resultsmentioning

confidence: 99%

“…A critical review of the available clinical evidence for the usefulness of riboflavin in migraine headache brings to light many questions. The majority of single ingredient adult trials have been 3 months 40,43,44,52 in duration with one exception. 42 In addition to a critical evaluation of clinical trial data, questions arise from the available pharmacokinetic and pharmacogenomic data.…”

Section: What Is New and Conclusionmentioning

confidence: 99%

“…A critical review of the available clinical evidence for the usefulness of riboflavin in migraine headache brings to light many questions. The majority of single ingredient adult trials have been 3 monthsin duration with one exception . It takes at least 2 months to obtain a maximal therapeutic effect from riboflavin and perhaps longer in some patients.…”

Section: What Is New and Conclusionmentioning

confidence: 99%

See 1 more Smart Citation

Prophylaxis of migraine headaches with riboflavin: A systematic review

Thompson

Saluja

2017

J Clin Pharm Ther

View full text Add to dashboard Cite

SummaryWhat is known and objective: Migraine headache is a relatively common, debilitating condition that costs our healthcare system over 78 billion dollars per year. Riboflavin has been advocated as a safe, effective prophylactic therapy for the prevention of migraines. The purpose of this study was to provide a systematic review of the current role of riboflavin in the prophylaxis of migraine headache. Methods What is new and conclusion:Riboflavin is well tolerated, inexpensive and has demonstrated efficacy in the reduction of adult patient's migraine headache frequency.Additional data are needed, however, to resolve questions involving pharmacokinetic issues and pharmacogenomic implications of therapy. K E Y W O R D Smigraine, pharmacogenomics, pharmacokinetics, riboflavin | WHAT IS KNOWN AND OBJECTIVEMigraine headache is a common, often disabling neurologic condition characterized by painful headaches associated with nausea, vomiting, and hypersensitivity to visual, auditory, and olfactory stimuli. The worldwide prevalence of migraine headache is about 10%; however, it is slightly higher in the United States at 12%.1,2 Women experience migraine headache at a greater rate (15%-17%) as compared to men. 1,3Epidemiologic data suggest that while 38% of patients with migraine headache need prophylactic therapy, only 3%-13% currently take prophylactic treatment. 4 Prophylactic therapy should be considered in situations where the patient feels that the recurring migraine headaches interfere with their daily routines and responsibilities despite acute treatment. 1-4The goals of treatment for patients requiring prophylactic therapy are to decrease the frequency, duration and severity of attacks,

show abstract

“…Two previous systematic reviews that evaluated the role of riboflavin in the prevention of migraine assessed the same studies (three RCTs and one retrospective study) [ 20 , 21 ]. Among these studies, two—one RCT and one retrospective study—reported that riboflavin was effective [ 22 , 23 ], while the other two reported ineffectiveness [ 24 , 25 ]. The latter two studies concluded that there was a lack of evidence to support the use of riboflavin for pediatric migraine.…”

Section: Resultsmentioning

confidence: 99%

Complementary and Integrative Medicines as Prophylactic Agents for Pediatric Migraine: A Narrative Literature Review

Yamanaka

Kanou

Takamatsu

et al. 2021

JCM

View full text Add to dashboard Cite

Complementary and integrative medicines (CIMs) are increasingly used as a preventive antimigraine therapy. In this review, we aimed to summarize the evidence for the efficacy and safety of eight CIMs (riboflavin, coenzyme Q10, magnesium, melatonin, polyunsaturated fatty acids, and combination therapy of feverfew, vitamin D, and ginkgolide B) in pediatric migraine prevention. The level of evidence for riboflavin was relatively high; it was investigated by many studies with five/seven studies demonstrating its efficacy. Five studies investigated the use of melatonin, with one reporting negative results. There was insufficient evidence on the effectiveness of coenzyme Q10, magnesium, and polyunsaturated fatty acids. Combination therapy showed positive potential; however, reports on the individual antimigraine effects of the CIMs were lacking. A definitive conclusion was not reached regarding the specific integrative drugs clinicians should choose for pediatric migraines, owing to low-quality evidence and a limited number of studies. Integrative medications are becoming more common for pediatric migraine prevention as they do not produce serious side effects, and underlying research data suggest their efficacy in preventing migraine. Additional studies are warranted to confirm the role of CIMs in treating patients with migraines.

show abstract

Riboflavin as migraine prophylaxis in adolescents

Abstract: Background Migraine is a cause of recurrent headaches in

Cited by 13 publications

References 0 publications

Non-Pharmacological Approaches for Migraine

Non-Pharmacological Approaches for Migraine

Prophylaxis of migraine headaches with riboflavin: A systematic review

Complementary and Integrative Medicines as Prophylactic Agents for Pediatric Migraine: A Narrative Literature Review

Contact Info

Product

Resources

About